CIK 0000899923 · Accelerated filer
MYRIAD GENETICS INC
Sign in to watch- Ticker
- MYGN
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 870494517
- Phone
- 801-584-3600
- Business address
- 322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
- Former names
- MYRIAD GENETICS INC
- 4 Shares withheld for taxes Chief Operating Officer gave up 2,055 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 549 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Technology Officer gave up 22,310 shares (to pay taxes)
- 4 Shares withheld for taxes Chief People Officer gave up 14,683 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 37,799 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Legal Officer gave up 5,995 shares (to pay taxes)
- 4 Grant or award Chief Commerical Officer acquired 226,804 shares (grant or award)
- 4 Shares withheld for taxes Chief Operating Officer gave up 29,289 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 4,752 shares (to pay taxes)
- 4 Shares withheld for taxes President and CEO gave up 47,120 shares (to pay taxes)
- 4 Open-market buy President and CEO bought 40,000 shares at $5.00 ($199,844)
- EFFECT Other Notice of Effectiveness
- 424B3 Offering Prospectus
- 4 Shares withheld for taxes Chief People Officer gave up 1,675 shares (to pay taxes)
- CORRESP Other Correspondence Between Filers and SEC Staff
- 4 Open-market buy Director bought 104,507 shares at an average $4.73 ($494,722)
- UPLOAD Other SEC-generated Letter
- S-3 Offering Registration Statement
- 10-K Report Annual Report
- 8-K Event Results of operations
Page 4 of 104 · 2,077 filings